Human Immunodeficiency Virus (HIV) Infection
Retroviruses are enveloped RNA viruses defined by their mechanism of replication via reverse transcription to produce DNA copies that integrate in the host cell genome. Several retroviruses, including 2 types of HIV and 2 types of human T-lymphotropic virus (HTLV—see HTLV Infections), cause serious disorders in people.
HIV-1 causes most HIV infections worldwide, but HIV-2 causes a substantial proportion of infections in parts of West Africa. In some areas of West Africa, both viruses are prevalent and may coinfect patients. HIV-2 appears to be less virulent than HIV-1.
HIV-1 originated in Central Africa in the first half of the 20th century, when a closely related chimpanzee virus first infected humans. Epidemic global spread began in the late 1970s, and AIDS was recognized in 1981.
The World Health Organization (WHO) estimates (1) that in 2017, about 36.9 million people, including 1.8 million children (< 15 years), were living with HIV worldwide; of the total, about 25.7 million live in sub-Saharan Africa. About 25% of people living with HIV were undiagnosed. Among people who knew they were infected, 79% were accessing treatment. In 2017, about 940,000 people died from AIDS-related illnesses worldwide (70% in sub-Saharan Africa), compared to 1.9 million in 2004 and 1.4 million in 2010. In 2017, about 1.8 million people, including 180,000 children, were newly infected with HIV, compared to 3.4 million new infections in 1996. Most new infections (95%) now occur in the developing world; over half are in women in sub-Saharan Africa. In many sub-Saharan African countries, incidence of HIV infection is declining markedly from the very high rates of a decade before; nevertheless, important gaps remain to meet the World Health Organization's Fast-Track strategy to end the AIDS epidemic by 2030.
In the United States in 2015, > 1.1 million people aged ≥ 13 years were estimated to be living with HIV infection; HIV was undiagnosed in about 15% of them. Overall, the number of new cases decreased by 19% from 2005 to 2014. In 2016, 39,782 cases were diagnosed. Over two thirds (67% or 26,570) of new infections occurred in gay and bisexual men. Among gay and bisexual men, the number of new infections was 10,223 in black/African American men, 7,425 in Hispanic/Latino men, and 7,390 in white men (2).
AIDS
AIDS is defined as one or more of the following:
-
HIV infection that leads to any of certain illnesses (see sidebar AIDS-Defining Illnesses [3])
-
A CD4+ T lymphocyte (helper cell) count of < 200/mcL
-
A CD4+ cell percentage of ≤ 14%
AIDS-defining illnesses are
-
Serious opportunistic infections
-
Certain cancers (eg, Kaposi sarcoma, non-Hodgkin lymphoma) to which defective cell-mediated immunity predisposes
-
Neurologic dysfunction
General references
-
1. UNAIDS.org: Fact Sheet: Latest Statistics on the Status of the AIDS epidemic.
-
2. Centers for Disease Control and Prevention (CDC): HIV in the United States: At a Glance.
-
3. Selik RM, Mokotoff ED, Branson, B, et al: Revised Surveillance Case Definition for HIV Infection—United States, 2014. MMWR63(RR03):1–10, 2014.
Transmission
Transmission of HIV requires contact with body fluids—specifically blood, semen, vaginal secretions, breast milk, saliva, or exudates from wounds or skin and mucosal lesions—that contain free HIV virions or infected cells. Transmission is more likely with the high levels of virions that are typical during primary infection, even when such infections are asymptomatic. Transmission by saliva or droplets produced by coughing or sneezing, although conceivable, is extremely unlikely.
HIV is not transmitted by casual nonsexual contact as may occur at work, school, or home.
Transmission is usually
Sexual transmission of HIV
Sexual practices such as fellatio and cunnilingus appear to be relatively low risk but not absolutely safe (see table HIV Transmission Risk for Several Sexual Activities). Risk does not increase significantly if semen or vaginal secretions are swallowed. However, open sores in the mouth may increase risk.
The sexual practices with the highest risks are those that cause mucosal trauma, typically intercourse. Anal-receptive intercourse poses the highest risk. Mucous membrane inflammation facilitates HIV transmission; sexually transmitted diseases, such as gonorrhea, chlamydial infection, trichomoniasis, and especially those that cause ulceration (eg, chancroid, herpes, syphilis), increase the risk several-fold. Other practices that cause mucosal trauma include fisting (inserting most or all of the hand into the rectum or vagina) and using sexual toys. When used during intercourse with an HIV-infected partner and/or with multiple concurrent sex partners, these practices increase the risk of HIV transmission.
In heterosexuals, the estimated risk per coital act is about 1/1000; however, risk is increased in the following:
Circumcision seems to reduce the risk of males acquiring HIV infection by about 50% by removing the penile mucosa (underside of foreskin), which is more susceptible to HIV infection than the keratinized, stratified squamous epithelium that covers the rest of the penis.
Recent evidence shows that HIV infected people in whom antiretroviral therapy has reduced their viral load below the current detectable level (virally suppressed) do not sexually transmit the virus to their partners. Undetectable virus equals an untransmittable virus.
HIV Transmission Risk for Several Sexual Activities
Needle- and instrument-related transmission
Risk of HIV transmission after skin penetration with a medical instrument contaminated with infected blood is on average about 1/300 without postexposure antiretroviral prophylaxis. Immediate prophylaxis probably reduces risk to < 1/1500. Risk appears to be higher if the wound is deep or if blood is inoculated (eg, with a contaminated hollow-bore needle). Risk is also increased with hollow-bore needles and with punctures of arteries or veins compared with solid needles or other penetrating objects coated with blood because larger volumes of blood may be transferred. Thus, sharing needles that have entered the veins of other injection drug users is a very high risk activity.
Risk of transmission from infected health care practitioners who take appropriate precautions is unclear but appears minimal. In the 1980s, one dentist transmitted HIV to ≥ 6 of his patients by unknown means. However, extensive investigations of patients cared for by other HIV-infected physicians, including surgeons, have uncovered few other cases.
Maternal transmission
HIV can be transmitted from mother to offspring
Without treatment, risk of transmission at birth is about 25 to 35%.
HIV is excreted in breast milk, and breastfeeding by untreated HIV-infected mothers may transmit HIV to about 10 to 15% of infants who had previously escaped infection.
Transmission rates can be reduced dramatically by treating HIV-positive mothers with antiretroviral drugs while they are pregnant, in labor, and breastfeeding.
Cesarean delivery and treatment of the infant for several weeks after birth also reduce the risk.
Because many HIV-positive pregnant women are treated or take prophylactic drugs, the incidence of AIDS in children is decreasing in many countries (see Human Immunodeficiency Virus (HIV) Infection in Infants and Children).
Transfusion- and transplant-related transmission
Screening of blood donors with tests for both antibody to HIV and HIV RNA has minimized risk of transmission via transfusion. Current risk of transmitting HIV via blood transfusion is probably < 1/2,000,000 per unit transfused in the United States. However, in many developing countries, where blood and blood products are not screened for HIV, the risk of transfusion-transmitted HIV infection remains high.
Rarely, HIV has been transmitted via transplantation of organs from HIV-seropositive donors. Infection has developed in recipients of kidney, liver, heart, pancreas, bone, and skin—all of which contain blood—but screening for HIV greatly reduces risk of transmission. HIV transmission is even more unlikely from transplantation of cornea, ethanol-treated and lyophilized bone, fresh-frozen bone without marrow, lyophilized tendon or fascia, or lyophilized and irradiated dura mater.
HIV transmission is possible via artificial insemination using sperm from HIV-positive donors. Some cases of infection occurred in the early 1980s, before safeguards were introduced.
In the United States, sperm washing is considered an effective method of reducing the risk of partner insemination from a known HIV-positive sperm donor.
Epidemiology
HIV has spread in 2 epidemiologically distinct patterns:
In most countries, both patterns occur, but the first pattern usually predominates in developed countries; the second pattern predominates in Africa, South America, and southern Asia.
In areas where heterosexual transmission is dominant, HIV infection follows routes of trade, transportation, and economic migration to cities and spreads secondarily to rural areas. In Africa, particularly southern Africa, the HIV epidemic has killed tens of millions of young adults, creating millions of orphans. Factors that perpetuate spread include
However, through international efforts, as of 2016, an estimated 19.5 million people living with HIV were accessing antiretroviral therapy, dramatically reducing deaths and transmission in many countries.
Many opportunistic infections that complicate HIV are reactivations of latent infections. Thus, epidemiologic factors that determine the prevalence of latent infections also influence risk of specific opportunistic infections. In many developing countries, prevalence of latent TB and toxoplasmosis in the general population is higher than that in developed countries. Dramatic increases in reactivated TB and toxoplasmic encephalitis have followed the epidemic of HIV-induced immunosuppression in these countries. Similarly in the United States, incidence of coccidioidomycosis, common in the Southwest, and histoplasmosis, common in the Midwest, has increased because of HIV infection.
Human herpesvirus 8 infection, which causes Kaposi sarcoma, is common among homosexual and bisexual men but uncommon among other HIV patients in the United States and Europe. Thus, in the United States, > 90% of AIDS patients who have developed Kaposi sarcoma are homosexual or bisexual men.
Pathophysiology
HIV attaches to and penetrates host T cells via CD4+ molecules and chemokine receptors (see figure Simplified HIV life cycle). After attachment, HIV RNA and several HIV-encoded enzymes are released into the host cell.
Viral replication requires that reverse transcriptase (an RNA-dependent DNA polymerase) copy HIV RNA, producing proviral DNA; this copying mechanism is prone to errors, resulting in frequent mutations and thus new HIV genotypes. These mutations facilitate the generation of HIV that can resist control by the host’s immune system and by antiretroviral drugs.
Proviral DNA enters the host cell’s nucleus and is integrated into the host DNA in a process that involves integrase, another HIV enzyme. With each cell division, the integrated proviral DNA is duplicated along with the host DNA. Subsequently, the proviral HIV DNA can be transcribed to HIV RNA and translated to HIV proteins, such as the envelope glycoproteins 41 and 120. These HIV proteins are assembled into HIV virions at the host cell inner membrane and budded from the cell surface within an envelop of modified human cell membrane. Each host cell may produce thousands of virions.
After budding, protease, another HIV enzyme, cleaves viral proteins, converting the immature virion into a mature, infectious virion.
Simplified HIV life cycle
Infected CD4+ lymphocytes produce > 98% of plasma HIV virions. A subset of infected CD4+ lymphocytes constitutes a reservoir of HIV that can reactivate (eg, if antiviral treatment is stopped).
Virions have a plasma half-life of about 6 hours. In moderate to heavy HIV infection, about 108 to 109 virions are created and removed daily. The high volume of HIV replication and high frequency of transcription errors by HIV reverse transcriptase result in many mutations, increasing the chance of producing strains resistant to host immunity and drugs.
Immune system
Two main consequences of HIV infection are
CD4+ lymphocytes are involved in cell-mediated and, to a lesser extent, humoral immunity. CD4+ depletion may result from the following:
Infected CD4+ lymphocytes have a half-life of about 2 days, which is much shorter than that of uninfected CD4+ cells. Rates of CD4+ lymphocyte destruction correlate with plasma HIV level. Typically, during the initial or primary infection, HIV levels are highest (> 106 copies/mL), and the CD4 count drops rapidly.
The normal CD4 count is about 750/mcL, and immunity is minimally affected if the count is > 350/mcL. If the count drops below about 200/mcL, loss of cell-mediated immunity allows a variety of opportunistic pathogens to reactivate from latent states and cause clinical disease.
The humoral immune system is also affected. Hyperplasia of B cells in lymph nodes causes lymphadenopathy, and secretion of antibodies to previously encountered antigens increases, often leading to hyperglobulinemia. Total antibody levels (especially IgG and IgA) and titers against previously encountered antigens may be unusually high. However, antibody response to new antigens (eg, in vaccines) decreases as the CD4 count decreases.
Abnormal elevation of immune activation may be caused in part by absorption of components of bowel bacteria. Immune activation contributes to CD4+ depletion and immunosuppression by mechanisms that remain unclear.
Other tissues
HIV also infects nonlymphoid monocytic cells (eg, dendritic cells in the skin, macrophages, brain microglia) and cells of the brain, genital tract, heart, and kidneys, causing disease in the corresponding organ systems.
HIV strains in several compartments, such as the nervous system (brain and CSF) and genital tract (semen), can be genetically distinct from those in plasma, suggesting that they have been selected by or have adapted to these anatomic compartments. Thus, HIV levels and resistance patterns in these compartments may vary independently from those in plasma.
Disease progression
During the first few weeks of primary infection, there are humoral and cellular immune responses:
-
Humoral: Antibodies to HIV are usually measurable within a few weeks after primary infection; however, antibodies cannot fully control HIV infection because mutated forms of HIV that are not controlled by the patient’s current anti-HIV antibodies are generated.
-
Cellular: Cell-mediated immunity is a more important means of controlling the high levels of viremia (usually over 106 copies/mL) at first. But rapid mutation of viral antigens that are targeted by lymphocyte-mediated cytotoxicity subvert control of HIV in all but a small percentage of patients.
Plasma HIV virion levels, expressed as number of HIV RNA copies/mL, stabilize after about 6 months at a level (set point) that varies widely among patients but averages 30,000 to 100,000/mL (4.2 to 5 log10/mL). The higher this set point, the more quickly the CD4 count decreases to a level that seriously impairs immunity (< 200/mcL) and results in the opportunistic infections and cancers that define AIDS.
Risk and severity of opportunistic infections, AIDS, and AIDS-related cancers are determined by 2 factors:
Risk of specific opportunistic infections increases below threshold CD4 counts of about 200/mcL for some infections and 50/mcL for others, as in the following:
-
CD4 count < 200/mcL: Increased risk of Pneumocystis jirovecii pneumonia, toxoplasmic encephalitis, and cryptococcal meningitis
-
CD4 count < 50/mcL: Increased risk of cytomegalovirus (CMV) and Mycobacterium avium complex (MAC) infections
For every 3-fold (0.5 log10) increase in plasma HIV RNA in untreated patients, risk of progression to AIDS or death over the next 2 to 3 years increases about 50%.
Without treatment, risk of progression to AIDS is about 1 to 2%/year in the first 2 to 3 years of infection and about 5 to 6%/year thereafter. Eventually, AIDS almost invariably develops in untreated patients.
Symptoms and Signs
Initial HIV infection
Initially, primary HIV infection may be asymptomatic or cause transient nonspecific symptoms (acute retroviral syndrome).
Acute retroviral syndrome usually begins within 1 to 4 weeks of infection and usually lasts 3 to 14 days. Symptoms and signs are often mistaken for infectious mononucleosis or benign, nonspecific viral syndromes and may include fever, malaise, fatigue, several types of dermatitis, sore throat, arthralgias, generalized lymphadenopathy, and septic meningitis.
After the first symptoms disappear, most patients, even without treatment, have no symptoms or only a few mild, intermittent, nonspecific symptoms for a highly variable time period (2 to 15 years).
Symptoms during this relatively asymptomatic period may result from HIV directly or from opportunistic infections. The following are most common:
Asymptomatic, mild-to-moderate cytopenias (eg, leukopenia, anemia, thrombocytopenia) are also common. Some patients experience progressive wasting (which may be related to anorexia and increased catabolism due to infections) and low-grade fevers or diarrhea.
Worsening HIV infection
When the CD4 count drops to < 200/mcL, nonspecific symptoms may worsen and a succession of AIDS-defining illnesses develop (see sidebar AIDS-Defining Illnesses).
In patients with HIV infection, certain syndromes are common and may require different considerations (see table Common Manifestations of HIV Infection by Organ System). Some patients present with cancers (eg, Kaposi sarcoma, B-cell lymphomas) that occur more frequently, are unusually severe, or have unique features in patients with HIV infection (see Cancers Common in HIV-Infected Patients). In other patients, neurologic dysfunction may occur.
Evaluation may detect infections that do not typically occur in the general population, such as
-
Disseminated mycobacterial infections
-
P. jirovecii infection
-
Cryptococcus neoformans infection
-
Other fungal infections
Infections that also occur in the general population but suggest AIDS if they are unusually severe or frequently recur include
Kaposi sarcoma (KS) is a vascular tumor caused by herpesvirus type 8 infection. AIDS-associated KS is an aggressive, multicentric tumor that may involve the face, trunk, mucosal surfaces, lymphatics, or GI tract. Lesions appear as bluish to violaceous macules, plaques, or tumors.
Purplish red nodules over the lower eyelid skin in an HIV-positive patient suggest Kaposi sarcoma.
This photo shows violaceous plaques on the forearm in a male with HIV infection.
Common Manifestations of HIV Infection by Organ System
Syndrome |
Cause |
Diagnostic Evaluation |
Treatment |
Symptoms/Comments/Comments |
Cardiac |
||||
|
Direct viral damage to cardiac myocytes |
Echocardiography |
Antiretroviral drugs |
Symptoms of heart failure |
|
GI |
||||
|
Candidiasis, CMV, or herpes simplex virus |
Esophagoscopy with biopsy of ulcers |
Treatment of cause |
Dysphagia, anorexia |
|
|
Gastroenteritis or colitis |
Intestinal Salmonella, MAC, Cryptosporidium (cryptosporidiosis), Cyclospora (cyclosporiasis), CMV, microsporidia, Cystoisospora (Isospora) belli (cystoisosporiasis), or Clostridium difficile |
Cultures and stains of stools or biopsy, but determination of cause possibly difficult |
For all, supportive treatment for symptoms, treatment of cause, and prompt initiation of antiretroviral drugs, as for the following: |
Diarrhea, weight loss, abdominal cramping |
|
Cholecystitis or cholangitis |
CMV, Cryptosporidium, Cyclospora, or microsporidia |
Ultrasonography or endoscopy |
Antiretroviral drugs for Cryptosporidium, Cyclospora, and microsporidia |
Possibly pain or obstruction |
|
Herpes simplex virus Genital warts or anal cancer induced by HPV
|
Examination Gram staining and culture Biopsy |
Treatment of cause |
High incidence in homosexual men who are infected with HPV via anal receptive sexual intercourse |
|
|
Hepatocellular damage due to hepatitis viruses, opportunistic infections, or antiviral drug toxicity |
TB, MAC, CMV, or peliosis (bartonellosis) Chronic hepatitis B or chronic hepatitis C, which may be worsened by HIV |
Differentiation from hepatitis due to antiretroviral or other drugs Liver biopsy sometimes necessary |
Treatment of cause |
Symptoms of hepatitis (eg, anorexia, nausea, vomiting, jaundice) |
Gynecologic |
||||
|
Vaginal candidiasis |
Candida |
Possibly increased in severity or recurrent |
||
|
Pelvic inflammatory disease |
Neisseria gonorrhoeae, Chlamydia trachomatis, or other usual pathogens |
Possibly increased in severity, atypical, and difficult to treat |
||
Hematologic |
||||
|
Anemia |
Multifactorial: HIV-induced bone marrow suppression Immune-mediated peripheral destruction Anemia of chronic disease Infections, particularly human parvovirus B-19, disseminated MAC, or histoplasmosis Cancers |
For parvovirus B19 infection, bone marrow examination (to check for multinucleated erythroblasts) or serum or bone marrow PCR |
Treatment of cause Transfusion as needed Erythropoietin for anemia due to antineoplastic drugs or zidovudine if severity warrants transfusion and erythropoietin level is < 500 mU/L IVIG for parvovirus |
With parvovirus, sometimes acute severe anemia |
|
Immune thrombocytopenia, drug toxicity, HIV-induced marrow suppression, immune-mediated peripheral destruction, infections, or cancer |
CBC, clotting tests, PTT, peripheral smear, bone marrow biopsy, or von Willebrand factor measurement |
Antiretroviral drugs IVIG for bleeding or preoperatively Possibly anti-Rho (D) IgG, vincristine, danazol, or interferon If severe and intractable, splenectomy |
Often asymptomatic and may occur in otherwise asymptomatic HIV infection |
|
|
HIV-induced bone marrow suppression, immune-mediated peripheral destruction, infections, cancer, or drug toxicity |
For severe neutropenia (< 500/mcL) plus fever, immediate broad-spectrum antibiotics If drug-induced, granulocyte or granulocyte-macrophage colony-stimulating factors |
— |
||
Neurologic |
||||
|
Mild to severe cognitive impairment with or without motor deficits |
Direct virus-induced brain damage |
HIV RNA level in CSF CT or MRI to check for brain atrophy (nonspecific) |
Antiretroviral drugs, which may reverse damage and improve function, although low levels of cognitive dysfunction commonly persist, even in treated patients |
Progression to dementia uncommon in treated patients |
|
Ascending paralysis |
Guillain-Barré syndrome or CMV polyradiculopathy |
Spinal cord MRI CSF testing |
Treatment of CMV polyradiculopathy Supportive care for Guillain-Barré syndrome |
Neutrophilic pleocytosis in patients with CMV polyradiculopathy, possibly simulating bacterial meningitis |
|
Acute or subacute focal encephalitis |
Toxoplasma gondii (toxoplasmosis) |
CT or MRI to check for ring-enhancing lesions, especially near basal ganglia Antibody testing of CSF (sensitive but not specific) PCR testing to check for T. gondii DNA in CSF Brain biopsy (rarely indicated) |
Pyrimethamine, folinic acid, sulfadiazine, and possibly trimethoprim/sulfamethoxazole (clindamycin if allergic to sulfa—see Toxoplasmosis : Treatment of patients with AIDS or other immunocompromising conditions) Often lifelong maintenance therapy |
Primary prophylaxis with clindamycin and pyrimethamine or trimethoprim/ sulfamethoxazole (as for Pneumocystis pneumonia) indicated for patients with a CD4 count of < 100/mcL and previous toxoplasmosis or positive antibodies; can be stopped if CD4 counts increase to > 200/mcL for ≥ 3 months in response to antiretroviral therapy |
|
Subacute encephalitis |
Less often, herpes simplex virus or varicella-zoster virus |
CSF PCR Response to treatment |
Antiviral drugs |
With CMV, often delirium, cranial nerve palsies, myoclonus, seizures, and progressively impaired consciousness at presentation Often responds rapidly to treatment |
|
Myelitis or polyradiculopathy |
CMV |
Spinal cord MRI CSF PCR |
Antiviral drugs |
Simulates Guillain-Barré syndrome |
|
Progressive encephalitis of white matter only |
Progressive multifocal leukoencephalopathy due to reactivation of latent JC virus infection HIV |
Brain MRI CSF testing |
Antiretroviral drugs to reverse the immunodeficiency (no drugs are effective for JC virus) |
Usually fatal within a few months May respond to antiretroviral drugs |
|
Coccidioidomycosis, Cryptococcus (cryptococcosis), Histoplasma (histoplasmosis), or Mycobacterium tuberculosis |
CT or MRI CSF stains, antigen tests, and cultures |
Treatment of cause |
Outcomes improved by early treatment |
|
|
Direct effects of HIV or CMV or antiviral drug toxicity |
History Sensory and motor testing |
Treatment of cause or withdrawal of toxic drugs |
Very common Not quickly reversible |
|
Ophthalmologic |
||||
|
Retinitis |
Direct retinoscopy |
Specific anti-CMV drugs |
Requires examination by specialist |
|
Oral |
||||
|
Oral candidiasis |
Immunosuppression by HIV |
Examination |
Systemic antifungals |
Possibly painless in early stages |
|
Intraoral ulcers |
Herpes simplex virus or aphthous stomatitis |
For aphthous ulcers, intralesional or systemic corticosteroids and systemic montelukast and thalidomide For herpes, acyclovir |
May be severe and result in undernutrition |
|
|
Mixed oral bacterial flora |
Examination |
Improved hygiene and nutrition Antibiotics |
May be severe, with bleeding, swelling, and tooth loss |
|
|
Painless intraoral mass |
Kaposi sarcoma, lymphoma, or tumors induced by HPV |
Biopsy |
Treatment of neoplasm |
— |
|
Painless white filiform patches on the sides of the tongue (oral hairy leukoplakia) |
Examination |
Acyclovir |
Usually asymptomatic |
|
Pulmonary |
||||
|
Subacute (occasionally acute) pneumonia |
Mycobacteria, fungi such as P. jirovecii, C. neoformans, H. capsulatum, Coccidioides immitis, or Aspergillus |
Pulse oximetry Chest x-ray Skin tests (sometimes false-negative because of anergy) Bronchoscopy with special stains and cultures of bronchial lavage specimens sometimes necessary |
Treatment of cause |
Possibly cough, tachypnea, and chest discomfort at presentation Mild hypoxia or increased alveolar-arterial oxygen gradient possibly occurring before evidence of pneumonia on x-ray |
|
Acute (occasionally subacute) pneumonia |
Typical bacterial pathogens or Haemophilus, Pseudomonas, Nocardia, or Rhodococcus |
In patients with known or suspected HIV and pneumonia, exclusion of opportunistic or unusual pathogens |
Treatment of cause |
Possibly cough, tachypnea, and chest discomfort at presentation |
|
Tracheobronchitis |
Candida or herpes simplex virus |
— |
Treatment of cause |
Possibly cough, tachypnea, and chest discomfort at presentation |
|
Subacute or chronic pneumonia or mediastinal adenopathy |
Kaposi sarcoma or B-cell lymphoma |
Chest CT Bronchoscopy |
Treatment of cause |
Possibly cough, tachypnea, and chest discomfort at presentation |
Renal |
||||
|
Nephrotic syndrome or renal insufficiency |
Direct viral damage, resulting in focal glomerulosclerosis |
Renal biopsy |
Antiretroviral drugs or ACE inhibitors possibly useful |
Increased incidence in African Americans and patients with a low CD4 count |
|
Tubular dysfunction (glucosuria, proteinuria) |
Some antiviral drugs |
Urinalysis and/or blood tests |
Dose reduction or discontinuation of the antiviral drug |
— |
Skin |
||||
|
Varicella-zoster virus |
Acyclovir or related drugs |
Common Possible prodrome of mild to severe pain or tingling before skin lesions |
||
|
Herpes simplex ulcers |
Usually clinical evaluation |
Antiviral drugs if lesions are severe, extensive, persistent, or disseminated |
Atypical lesions of herpes simplex that are extensive, severe, or persistent |
|
|
Sarcoptes scabiei |
Clinical evaluation and scrapings |
Possibly severe hyperkeratotic lesions |
||
|
Violaceous or red papules or nodules |
Kaposi sarcoma or bartonellosis |
Biopsy |
Antiretroviral drugs and treatment of cause |
— |
|
Centrally umbilicated skin lesions |
Cryptococcosis or molluscum contagiosum |
May be the presenting sign of cryptococcemia |
||
Systemic |
||||
|
Sepsis and septic shock due to nosocomial gram-negative bacillary and staphylococcal infections, disseminated opportunistic infections |
Gram-negative bacilli, Staphylococcus aureus, Candida, Salmonella, M. tuberculosis, MAC, or H. capsulatum |
Blood cultures Bone marrow examination |
Treatment of cause |
— |
|
Wasting syndrome (substantial weight loss) |
Multifactorial, including AIDS, AIDS-related opportunistic infections, AIDS-related cancers, and/or AIDS-induced hypogonadism |
Defined as weight loss of > 10% of body weight |
Antiretroviral drugs (the primary treatment for this syndrome) Treatment of underlying infections; treatment of AIDS-induced hypogonadism when indicated Measures to improve appetite and caloric intake |
— |
|
CMV = cytomegalovirus; HPV = human papillomavirus; IVIG = IV immune globulin; MAC =Mycobacterium avium complex; TMP/SMX = trimethoprim/sulfamethoxazole. |
||||
Diagnosis
HIV infection is suspected in patients with persistent, unexplained, generalized adenopathy or any of the AIDS-defining illnesses (see sidebar AIDS-Defining Illnesses). It may also be suspected in high-risk patients with symptoms that could represent acute primary HIV infection.
Diagnostic tests
Detection of antibodies to HIV is sensitive and specific except during the first few weeks after infection. Currently, a 4th-generation combination immunoassay is recommended; it detects antibodies to both HIV-1 and HIV-2 as well as the p24 HIV antigen (p24 is a core protein of the virus). The laboratory version is probably preferred over the point-of-care one for diagnosing early infection, but both can be done quickly (within 30 minutes). If the test result is positive, an assay to differentiate HIV-1 and HIV-2 and an HIV RNA assay are done.
Earlier-generation enzyme-linked immunosorbent assay (ELISA) antibody assays are highly sensitive, but because they do not test for antigen, they are not positive as early as the 4th-generation combination test. Also, results are rarely false-positive. Positive ELISA results are therefore confirmed with a more specific test such as Western blot. However, these tests have drawbacks:
Newer point-of-care tests using blood or saliva (eg, particle agglutination, immunoconcentration, immunochromatography) can be done quickly (in 15 minutes) and simply, allowing testing in a variety of settings and immediate reporting to patients. Positive results of these rapid tests should be confirmed by standard blood tests (eg, ELISA with or without Western blot) in developed countries and repetition with one or more other rapid tests in developing countries. Negative tests need not be confirmed.
If HIV infection is suspected despite negative antibody test results (eg, during the first few weeks after infection), the plasma HIV RNA level may be measured. The nucleic acid amplification assays used are highly sensitive and specific. HIV RNA assays require advanced technology, such as reverse transcription–PCR (RT-PCR), which is sensitive to extremely low HIV RNA levels. Measuring p24 HIV antigen by ELISA is less sensitive and less specific than directly detecting HIV RNA in blood.
Monitoring
When HIV is diagnosed, the following should be determined:
Both are useful for determining prognosis and monitoring treatment.
The CD4 count is calculated as the product of the following:
Using the numbers above, the CD4 count (4000 x 0.3 x 0.2) is 240 cells/mcL, or about 1/3 of the normal CD4 count in adults, which is about 750 ± 250/mcL.
Plasma HIV RNA level (viral load) reflects HIV replication rates. The higher the set point (the relatively stable virus levels that occur after primary infection), the more quickly the CD4 count decreases and the greater the risk of opportunistic infection, even in patients without symptoms.
Baseline HIV genotype can be determined using a sample of blood; availability of this testing varies by location. HIV genotyping is used to identify mutations known to cause resistance to certain antiretroviral drugs and to help select a drug regimen likely to be effective for a specific patient with HIV infection.
Staging
HIV-related conditions
Diagnosis of the various opportunistic infections, cancers, and other syndromes that occur in HIV-infected patients is discussed elsewhere in The Manual. Many have aspects unique to HIV infection.
Hematologic disorders (eg, cytopenias, lymphomas, cancers) are common and may be usefully evaluated with bone marrow aspiration and biopsy. This procedure can also help diagnose disseminated infections with MAC, M. tuberculosis, Cryptococcus, Histoplasma, human parvovirus B19, P. jirovecii, and Leishmania. Most patients have normocellular or hypercellular marrow despite peripheral cytopenia, reflecting peripheral destruction. Iron stores are usually normal or increased, reflecting anemia of chronic disease (an iron-reutilization defect). Mild to moderate plasmacytosis, lymphoid aggregates, increased numbers of histiocytes, and dysplastic changes in hematopoietic cells are common.
HIV-associated neurologic syndromes can be differentiated via lumbar puncture with CSF analysis and contrast-enhanced CT or MRI (see table Common Manifestations of HIV Infection by Organ System).
Screening for HIV
Screening antibody tests or newer combination antigen/antibody tests should be offered routinely to adults and adolescents, particularly pregnant women, regardless of their perceived risk. For people at highest risk, especially sexually active people who have multiple partners and who do not practice safe sex, testing should be repeated every 6 to 12 months. Such testing is confidential and available, often free of charge, in many public and private facilities throughout the world.
Prognosis
Risk of AIDS, death, or both is predicted by the
For every 3-fold (0.5 log10) increase in viral load, mortality over the next 2 to 3 years increases about 50%. HIV-associated morbidity and mortality vary by the CD4 count, with the most deaths from HIV-related causes occurring at counts of < 50/mcL. However, with effective treatment, the HIV RNA level decreases to undetectable levels, CD4 counts often increase dramatically, and risk of illness and death falls but remains higher than that for age-matched populations not infected with HIV.
Another, less well-understood prognostic factor is the level of immune activation as determined by evaluating the expression of activation markers on CD4 and CD8 lymphocytes. Activation, which may be caused by leakage of bacteria across the HIV-damaged colonic mucosa, is a strong prognostic predictor but is not used clinically because this test is not widely available and antiretroviral therapy changes the prognosis, making this test less important.
A subgroup of HIV-infected people (termed long-term nonprogressors) remains asymptomatic with high CD4 counts and low HIV levels in the blood without antiretroviral treatment. These people usually have vigorous cellular and humoral immune responses to their infecting HIV strain as measured by assays in vitro. The specificity of this effective response is shown by the following: When these people acquire a superinfection with a second strain of HIV to which their immune response is not as effective, they convert to a more typical pattern of progression. Thus, their unusually effective response to the first strain does not apply to the second strain. These cases provide a rationale for counseling HIV-infected people that they still need to avoid exposure to possible HIV superinfection through unsafe sex or needle sharing.
Cure of HIV infection has not been thought possible, and thus lifelong drug treatment is considered necessary. Patients living with HIV infection should be urged to take their antiretroviral drugs consistently. An instance of a possible cure was widely reported in an infant with transient eradication of replication-competent HIV after about 15 months of antiretroviral therapy. However, HIV replication subsequently resumed. In a large international clinical trial, risk of opportunistic infection or death from any cause, particularly from premature coronary artery disease, cerebrovascular events, or liver and kidney disorders, was significantly higher when antiretroviral therapy was taken episodically (guided by the CD4 count) than when it was taken continuously (1).
Prognosis reference
-
1. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 30;355 (22):2283–96, 2006.
Treatment
-
Combinations of antiretroviral drugs (antiretroviral therapy [ART], sometimes called highly active ART [HAART] or combined ART [cART])
-
Chemoprophylaxis for opportunistic infections in patients at high risk
(See also Drug Treatment of HIV Infection.)
Because disease-related complications can occur in untreated patients with high CD4 counts and because less toxic drugs have been developed, treatment with ART is now recommended for nearly all patients. The benefits of ART outweigh the risks in every patient group and setting that has been carefully studied. In the Strategic Timing of AntiRetroviral Treatment (START) study, 5472 treatment-naïve patients with HIV infection and CD4 counts > 350 cells/mcL were randomized to start ART immediately (immediate initiation) or to defer ART until their CD4 count decreased to < 250 cells/mcL(deferred initiation). Risk of AIDS-related events (eg, TB, Kaposi sarcoma, malignant lymphomas) and non-AIDS–related events (eg, non-AIDS cancer, cardiovascular disease) was lower in the immediate-initiation group (1).
A few exceptional patients can control their HIV strain without treatment; they maintain normal CD4 counts and very low blood levels of HIV (long-term nonprogressors) or normal CD4 counts and undetectable blood levels of HIV (elite controllers). These patients may not require ART, but studies to determine whether treating them is helpful have not been done and would be difficult because there are few of these patients and they would likely do well not taking ART for long periods.
Antiretroviral therapy: General principles
ART aims to
A poor CD4 count response is more likely if the CD4 count at initiation of treatment is low (especially if < 50/mcL) and/or the HIV RNA level is high. However, marked improvement is likely even in patients with advanced immunosuppression. An increased CD4 count correlates with markedly decreased risk of opportunistic infections, other complications, and death. With immune restoration, patients, even those with complications that have no specific treatment (eg, HIV-induced cognitive dysfunction) or that were previously considered untreatable (eg, progressive multifocal leukoencephalopathy), may improve. Outcomes are also improved for patients with cancers (eg, lymphoma, Kaposi sarcoma) and most opportunistic infections.
ART can usually achieve its goals if patients take their drugs > 95% of the time. However, maintaining this degree of adherence is difficult. Partial suppression (failure to lower plasma levels to undetectable levels) may select for single or multiple accumulated mutations in HIV that make viruses partially or completely resistant to a single drug or entire classes of drugs. Unless subsequent treatment uses drugs of other classes to which HIV remains sensitive, treatment is more likely to fail.
Patients with most acute opportunistic infections benefit from early ART (initiated during the management of the opportunistic infection). However, for some opportunistic infections, such as tuberculous meningitis or cryptococcal meningitis, the evidence suggests that ART should be delayed until the first phase of antimicrobial therapy for these infections is finished.
The success of ART is assessed by measuring plasma HIV RNA levels every 8 to 12 weeks for the first 4 to 6 months or until HIV levels are undetectable and every 3 to 6 months thereafter. Increasing HIV levels are the earliest evidence of treatment failure and may precede a decreasing CD4 count by months. Maintaining patients on failing drug regimens selects for HIV mutants that are more drug-resistant. However, compared with wild-type HIV, these mutants appear less able to reduce the CD4 count, and failing drug regimens are often continued when no fully suppressive regimen can be found.
If treatment fails, drug susceptibility (resistance) assays can determine the susceptibility of the dominant HIV strain to all available drugs. Genotypic and phenotypic assays are available and can help clinicians select a new regimen that should contain at least 2 and preferably 3 drugs to which the HIV strain is more susceptible. The dominant HIV strain in the blood of patients who are taken off antiretroviral therapy may revert over months to years to the wild-type (ie, susceptible) strain because the resistant mutants replicate more slowly and are replaced by the wild type. Thus, if patients have not been treated recently, the full extent of resistance may not be apparent through resistance testing, but when treatment resumes, strains with resistance mutations often reemerge from latency and again replace the wild-type HIV strain.
Many patients living with HIV infection are taking complex regimens involving multiple pills to control the HIV RNA level (viral load), but often, no conventional HIV RNA resistance tests were done when viral treatment failed. With the availability of new co-formulated HIV drugs, many patients could benefit from simplification of their ART regimen, guided by HIV DNA archive genotype testing (GenoSure Archive). The HIV DNA genotype archive provides HIV-1 antiretroviral drug resistance data when conventional HIV RNA resistance testing cannot be done because patients have a low plasma HIV RNA level (< 500 copies/mL). The HIV DNA archive genotype test analyzes integrated and unintegrated archived HIV-1 proviral DNA embedded in host cells. The test amplifies cell-associated HIV-1 DNA from infected cells in whole blood samples, then uses next-generation sequencing technology to analyze the HIV-1 polymerase region. The positive predictive value of the HIV DNA archive resistance test results may enable clinicians to identify HIV-resistance mutations that were previously unidentified and to select a potentially simpler regimen with co-formulated drugs (≥ 2 drugs in a single pill).
Immune reconstitution inflammatory syndrome (IRIS)
Patients beginning ART sometimes deteriorate clinically, even though HIV levels in their blood are suppressed and their CD4 count increases, because of an immune reaction to subclinical opportunistic infections or to residual microbial antigens after successful treatment of opportunistic infections. IRIS usually occurs in the first months of treatment but is occasionally delayed. IRIS can complicate virtually any opportunistic infection and even tumors (eg, Kaposi sarcoma) but is usually self-limited or responds to brief regimens of corticosteroids.
IRIS has two forms:
Paradoxical IRIS typically occurs during the first few months of treatment and usually resolves on its own. If it does not, corticosteroids, given for a short time, are often effective. Paradoxical IRIS is more likely to cause symptoms and symptoms are more likely to be severe when ART is started soon after treatment of an opportunistic infection is started. Thus, for some opportunistic infections, ART is delayed until treatment of the opportunistic infection has reduced or eliminated the infection.
In patients with unmasked IRIS, the newly identified opportunistic infection is treated with antimicrobial drugs. Occasionally, when the symptoms are severe, corticosteroids are also used. Usually, when unmasked IRIS occurs, ART is continued. An exception is cryptococcal meningitis. Then ART is temporarily interrupted until the infection is controlled.
Determining whether clinical deterioration is caused by treatment failure, IRIS, or both requires assessment of the persistence of active infections with cultures and can be difficult.
Interruption of antiretroviral therapy
Interruption of ART is usually safe if all drugs are stopped simultaneously, but levels of slowly metabolized drugs (eg, nevirapine) may remain high and thus increase the risk of resistance. Interruption may be necessary if intervening illnesses require treatment or if drug toxicity is intolerable or needs to be evaluated. After interruption to determine which drug is responsible for toxicity, clinicians can safely restart most drugs as monotherapy for up to a few days. Note: The most important exception is abacavir; patients who had fever or rash during previous exposure to abacavir may develop severe, potentially fatal hypersensitivity reactions with reexposure. Risk of an adverse reaction to abacavir is 100-fold higher in patients with HLA-B*57:01, which can be detected by genetic testing.
End-of-life care
Although antiretroviral therapy has dramatically increased life expectancy for patients with AIDS, many patients still deteriorate and die. Death may result from the following:
-
Inability to take ART consistently, resulting in progressive immunosuppression
-
Occurrence of untreatable opportunistic infections and cancers
-
Liver failure due to hepatitis B or C
-
Accelerated aging and age-related disorders
-
Non-AIDS–related cancers that occur at a higher rate in patients with otherwise well-controlled HIV infection
Death is rarely sudden; thus, patients usually have time to make plans. Nonetheless, patients should record their plans for health care early, with clear instructions for end-of-life care. Other legal documents, including powers of attorney and wills, should be in place. These documents are particularly important for homosexual patients because protection of assets and rights (including visitation and decision-making) for their partners may be problems.
As patients near the end of life, clinicians may need to prescribe drugs to relieve pain, anorexia, agitation, and other distressing symptoms. The profound weight loss in many people during the last stages of AIDS makes good skin care difficult. The comprehensive support provided by hospice programs helps many patients because hospice providers are unusually skilled at symptom management, and they support caregivers and patient autonomy.
Treatment reference
-
1. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al: Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373 (9):795–807, 2015. doi: 10.1056/NEJMoa1506816.
Prevention
Vaccines against HIV have been difficult to develop because HIV surface proteins mutate easily, resulting in an enormous diversity of antigenic types. Nonetheless, various vaccine candidates are under study, and a few have shown promise in clinical trials. At the present time, there is no effective AIDS vaccine.
Prevention of transmission
Vaginal microbicides (including antiretroviral drugs) inserted before sexual contact have thus far proved ineffective, and some appear to increase risk for women, perhaps by damaging natural barriers to HIV.
Effective measures include the following:
-
Public education: Education is effective and appears to have decreased rates of infection in some countries, notably Thailand and Uganda. Because sexual contact accounts for most cases, teaching people to avoid unsafe sex practices is the most relevant measure (see table HIV Transmission Risk for Several Sexual Activities).
-
Safe sex practices: Safe sex practices between an HIV-infected patient whose infection is not virally suppressed and partners who are not infected with HIV are essential to prevent the spread of the infection. Unless the HIV-infected partner is known to have a virally suppressed infection (ie, undetectable viral load) and the relationship remains monogamous, safe sex practices are essential. Virally suppressed people living with HIV do not sexually transmit the virus to their partners (that undetectable virus equals an untransmittable virus) (1). Safe sex practices are also advised when both partners are HIV-positive and not virally suppressed; unprotected sex between HIV-infected people who are virally unsuppressed may expose a person to resistant or more virulent strains of HIV and to other viruses (eg, cytomegalovirus, Epstein-Barr virus, herpes simplex virus, hepatitis B virus) that cause severe disease in AIDS patients, as well as to syphilis and other sexually transmitted diseases (STDs). Condoms offer the best protection. Oil-based lubricants should not be used because they may dissolve latex, increasing the risk of condom failure. (See also the CDC's information on HIV Transmission.)
-
Counseling for parenteral drug users: Counseling about the risk of sharing needles is important but is probably more effective if combined with provision of sterile needles, treatment of drug dependence, and rehabilitation.
-
Confidential testing for HIV infection: Testing should be offered routinely to adolescents and adults in virtually all health care settings. To facilitate routine testing, some states no longer require written consent or extensive pre-test counseling.
-
Counseling for pregnant women: Mother-to-child transmission has been virtually eliminated by HIV testing, treatment with ART, and, in developed countries, use of breast milk substitutes. If pregnant women test positive for HIV, risk of mother-to-child transmission should be explained. Pregnant women who do not accept immediate treatment for their HIV infection should be encouraged to accept therapy to protect the unborn baby, typically beginning at about 14 weeks gestation. Combination therapy is typically used because it is more effective than monotherapy and less likely to result in drug resistance. Some drugs can be toxic to the fetus or woman and should be avoided. If women meet criteria for ART, they should begin a regimen tailored to their history and stage of pregnancy and continue it throughout pregnancy. Cesarean delivery can also reduce risk of transmission. Regardless of the antepartum regimen used or mode of delivery, all HIV-infected women should be given IV zidovudine during labor, and after birth, neonates should be given oral zidovudine, which is continued for 6 weeks after delivery (see also Prevention of Perinatal Transmission). Some women choose to terminate their pregnancy because HIV can be transmitted in utero to the fetus or for other reasons.
-
Screening of blood and organs: Transmission by blood transfusion is still remotely possible in the United States because antibody results may be false-negative during early infection. Currently, screening blood for antibody and p24 antigen is mandated in the United States and probably further reduces risk of transmission. Risk is reduced further by asking people with risk factors for HIV infection, even those with recent negative HIV antibody test results, not to donate blood or organs for transplantation. The FDA has issued draft guidance for deferral of blood donation, including deferral for 12 months after the most recent sexual contact for men who have had sex with another man and for women who have had sex with a man who has had sex with another man (see Revised Recommendations for Reducing the Risk of HIV Transmission by Blood and Blood Products). However, use of sensitive HIV screening tests and deferral of donors of organs, blood, and blood products have not been implemented consistently in developing countries.
-
Preexposure prophylaxis with antiretrovirals (PrEP): In PrEP, people who are not infected with HIV but are at high risk (eg, by having an HIV-infected sex partner) take an antiretroviral drug daily to reduce their risk of infection. The combination of tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) can be used. Use of PrEP does not eliminate the need to use other methods of reducing risk of HIV infection, including using condoms and avoiding high-risk behaviors (eg, needle sharing). Data concerning infants of HIV-negative mothers taking TDF/FTC PrEP during pregnancy are incomplete, but currently, no adverse effects have been reported in children born to HIV-infected women treated with TDF/FTC. Use of PrEP to reduce the risk of HIV infection in injection drug users is being studied. For the current CDC recommendations, see Pre-Exposure Prophylaxis (PrEP).
-
Circumcision of men: In young African men, circumcision has been shown to reduce their risk of acquiring HIV infection from female partners during vaginal sex by about 50%; male circumcision is probably similarly effective elsewhere. Whether male circumcision reduces HIV transmission from HIV-positive men to women or reduces the risk of acquiring HIV from an infected male partner is unknown.
-
Universal precautions: Medical and dental health care practitioners should wear gloves in situations that may involve contact with any patient’s mucous membranes or body fluids and should be taught how to avoid needlestick accidents. Home caregivers of patients with HIV infection should wear gloves if their hands may be exposed to body fluids. Surfaces or instruments contaminated by blood or other body fluids should be cleaned and disinfected. Effective disinfectants include heat, peroxide, alcohols, phenolics, and hypochlorite (bleach). Isolation of HIV-infected patients is unnecessary unless indicated by an opportunistic infection (eg, TB). Guidelines to prevent transmission from infected practitioners to patients have not been established.
-
Treatment of HIV infection: Treatment with ART lowers the risk of transmission
Postexposure prophylaxis (PEP)
Potential consequences of exposure to HIV have prompted the development of policies and procedures, particularly preventive treatment, to decrease risk of infection to health care workers.
Preventive treatment is indicated after
Body fluids such as saliva, urine, tears, nasal secretions, vomitus, or sweat are not considered potentially infectious unless they are visibly bloody.
After initial exposure to blood, the exposed area is immediately cleaned with soap and water for skin exposures and with antiseptic for puncture wounds. If mucous membranes are exposed, the area is flushed with large amounts of water.
The following are documented:
Type of exposure is defined by
Risk of infection is about 0.3% (1:300) after a typical percutaneous exposure and about 0.09% (1:1100) after mucous membrane exposure. These risks vary, reflecting the amount of HIV transferred to the person with the injury; the amount of HIV transferred is affected by multiple factors, including viral load of the source and type of needle (eg, hollow or solid). However, these factors are no longer taken into account in PEP recommendations.
The source is qualified by whether it is known or unknown. If the source is unknown (eg, a needle on the street or in a sharps disposal container), risk should be assessed based on the circumstances of the exposure (eg, whether the exposure occurred in an area where injection drug use is prevalent, whether a needle discarded in a drug-treatment facility was used). If the source is known but HIV status is not, the source is assessed for HIV risk factors, and prophylaxis is considered (see table Postexposure Prophylaxis Recommendations).
Postexposure Prophylaxis Recommendations
Infection Status of Source |
Prophylaxis |
|
HIV-positive (symptomatic or asymptomatic HIV infection, AIDS, acute seroconversion, known or unknown viral load) |
PEP with ≥ 3 antiretroviral drugs |
|
Unknown HIV status of source or unknown source |
Generally, no PEP warranted*; however, consideration of PEP if source has HIV risk factors or if setting is likely to involve exposure to HIV-infected people |
|
HIV-negative (based on antibody tests or nucleic acid amplification assays) |
No PEP warranted |
|
*PEP is optional and should be based on an individualized decision by the exposed person and the treating clinician. If PEP is offered and taken and the source is later determined to be HIV-negative, PEP should be stopped. |
|
|
PEP =postexposure prophylaxis. |
|
|
Adapted from the World Health Organization: Guidelines on postexposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: Recommendations for a public health approach—December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. |
|
The goal is to start PEP as soon after exposure as possible if prophylaxis is warranted. CDC recommends providing PEP within 24 to 36 hours after exposure; a longer interval after exposure requires the advice of an expert.
Use of PEP is determined by risk of infection; guidelines recommend antiretroviral therapy with ≥ 3 antiretroviral drugs given for 28 days. The drugs should be carefully selected to minimize adverse effects and provide a convenient dosing schedule and thus encourage PEP completion. Preferred regimens include a combination of 2 NRTIs and an integrase inhibitor, either raltegravir or dolutegravir. In patients with childbearing potential, raltegravir is preferred because dolutegravir is possibly teratogenic during the first trimester of pregnancy—this is under epidemiologic investigation. Alternative regimens include 2 NRTIs plus a PI. For detailed recommendations, see the CDC's Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016 and dolutegravir-alert.pdf">Interim Statement Regarding Potential Fetal Harm from Exposure to Dolutegravir – Implications for HIV Post-exposure Prophylaxis (PEP).
If the source’s virus is known or suspected to be resistant to ≥ 1 drug, an expert in antiretroviral therapy and HIV transmission should be consulted. However, clinicians should not delay PEP pending expert consultation or drug susceptibility testing. Also, clinicians should provide immediate evaluation and face-to-face counseling and not delay follow-up care.
Prevention of opportunistic infections
(See also the United States Public Health Service and the HIV Medicine Association of the Infectious Diseases Society of America’s Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents.)
Effective chemoprophylaxis is available for many opportunistic infections and reduces rates of disease due to P. jirovecii, Candida, Cryptococcus, and MAC. If therapy restores CD4 counts to above threshold values for > 3 months, chemoprophylaxis can be stopped.
Primary prophylaxis depends on the CD4 count:
-
CD4 count < 200/mcL or oropharyngeal candidiasis (active or previous): Prophylaxis against P. jirovecii pneumonia is recommended. Double-strength trimethoprim/sulfamethoxazole (TMP/SMX) tablets given once/day or 3 times/week are effective. Some adverse effects can be minimized with the 3 times/week dose or by gradual dose escalation. Some patients who cannot tolerate TMP/SMX can tolerate dapsone (100 mg once/day). Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk for developing severe hemolysis with dapsone use and, therefore, should be screened for G6PD deficiency before using dapsone. For the few patients who cannot tolerate either drug because of a troublesome adverse effect (eg, fever, neutropenia, rash), aerosolized pentamidine 300 mg once/month or atovaquone 1500 mg once/day can be used.
-
CD4 count < 50/mcL: Prophylaxis against disseminated MAC consists of azithromycin or clarithromycin; if neither of these drugs is tolerated, rifabutin can be used. Azithromycin can be given weekly as two 600-mg tablets; it provides protection (70%) similar to daily clarithromycin and does not interact with other drugs.
If latent TB is suspected (based on tuberculin skin tests, interferon-gamma release assays, high-risk exposure, personal history of active TB, or residence in a region with high TB prevalence), regardless of CD4 count, patients should be given isoniazid 5 mg/kg (up to 300 mg) po once/day plus pyridoxine (vitamin B6) 10 to 25 mg po once/day for 9 months to prevent reactivation.
For primary prophylaxis against some fungal infections (eg, esophageal candidiasis, cryptococcal meningitis or pneumonia), oral fluconazole 100 to 200 mg once/day or 400 mg weekly is successful but is infrequently used because the cost per infection prevented is high and diagnosis and treatment of these infections are usually successful.
Secondary prophylaxis (after control of the initial infection) is indicated if patients have had the following:
-
Recurrent oral, vaginal, or esophageal candidiasis; coccidioidomycosis; or cryptococcal infections: Fluconazole is used.
-
Histoplasmosis: Itraconazole is used.
-
Latent toxoplasmosis: This asymptomatic condition is indicated by serum antibodies (IgG) to Toxoplasma gondii. TMP/SMX (in doses used to prevent P. jirovecii pneumonia) is used to prevent reactivation and consequent toxoplasmic encephalitis. Latent infection is less common (about 15% of adults) in the United States than in Europe and most developing countries (up to 70 to 80% of adults).
-
Aspergillosis (possibly)
Detailed guidelines for prophylaxis of fungal (including Pneumocystis), viral, mycobacterial, and toxoplasmic infections are available at www.aidsinfo.nih.gov.
Immunization
The CDC 2018 recommendations for vaccination of HIV-infected patients include the following:
-
Patients who have not received the conjugate pneumococcal vaccine (PCV13) or polysaccharide pneumococcal vaccine (PPSV23) should be given PCV13 followed by PPSV23 ≥ 8 weeks after PCV13.
-
All patients should be given the influenza vaccine annually.
-
All patients should be given the hepatitis B vaccine.
-
Patients at risk of hepatitis A or desiring protection from it should be given the hepatitis A vaccine.
-
At the appropriate age, males and females should be given the human papillomavirus (HPV) vaccine to prevent HPV-related cervical and anal cancers.
-
Adults who have not been previously vaccinated with the meningococcal vaccine should be given a 2-dose primary series of MenACWY ≥ 2 months apart.
-
If people have not previously received the tetanus-diphtheria-pertussis vaccine (Tdap), they should be given one dose of Tdap, followed by the tetanus-diphtheria vaccine (Td) booster every 10 years.
Generally, inactivated vaccines should be used. These vaccines are effective less often in patients who are HIV-positive than in those who are HIV-negative.
The herpes zoster vaccine (for boosting immunity to prevent reactivation as zoster) could be useful in HIV-infected adults. The original live-attenuated zoster vaccine is contraindicated in patients with a weakened immune system and if the CD4 count is < 200/mcL. However, the newer recombinant zoster vaccine is not contraindicated in patients with HIV, but recommendations regarding its use in these patients have not yet been made (see CDC 2019 Adult Conditions Immunization Schedule).
Because live-virus vaccines are potentially dangerous for patients with severe immunosuppression, expert opinion should be sought when dealing with patients at risk of primary varicella; recommendations vary (see vaccination information in HIV in Infants and Children and see table Considerations for Use of Live Vaccines in Children With HIV Infection).
Prevention reference
-
1. Rodger AJ, Cambiano V, Bruun T, et al: Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 316(2):171-81, 2016. doi: 10.1001/jama.2016.5148.
Key Points
-
HIV infects CD4+ lymphocytes and thus interferes with cell-mediated and, to a lesser extent, humoral immunity.
-
HIV is spread mainly by sexual contact, parenteral exposure to contaminated blood, and prenatal and perinatal maternal transmission.
-
Frequent viral mutations combined with immune system damage significantly impair the body's ability to clear the HIV infection.
-
Various opportunistic infections and cancers can develop and are the usual cause of death in untreated patients.
-
Diagnose using antibody tests, and monitor by measuring viral load and CD4 count.
-
Treat with a combination of antiretroviral drugs, which can restore immune function to nearly normal in most patients if they take the drugs consistently.
-
Periodically counsel patients living with HIV about safe sex, the importance of regular physical activity and a healthy diet, and stress management.
-
Use postexposure and preexposure antiretroviral prophylaxis when indicated.
-
Give primary prophylaxis against opportunistic infections based on the CD4 count.
More Information
Drugs Mentioned In This Article
| Drug Name | Select Trade |
|---|---|
immune globulin |
Gammagard S/D |
clarithromycin |
BIAXIN |
Pyrimethamine |
DARAPRIM |
emtricitabine |
EMTRIVA |
sulfadiazine |
No US brand name |
Itraconazole |
SPORANOX |
azithromycin |
ZITHROMAX |
dolutegravir |
Dolutegravir |
fluconazole |
DIFLUCAN |
montelukast |
SINGULAIR |
vincristine |
MARQIBO KIT |
clindamycin |
CLEOCIN |
thalidomide |
THALOMID |
raltegravir |
ISENTRESS |
pentamidine |
NEBUPENT |
zidovudine |
RETROVIR |
atovaquone |
MEPRON |
nevirapine |
VIRAMUNE |
isoniazid |
LANIAZID |
rifabutin |
MYCOBUTIN |
tenofovir |
VIREAD |
acyclovir |
ZOVIRAX |
abacavir |
ZIAGEN |
dapsone |
ACZONE |
